Causes of type 1 and type 2 diabetes
Reading File
Finding Sources
Finding Sources
Searching PubMed
"type 1 diabetes" AND "etiology" AND "pathogenesis"
Searching PubMed
"type 2 diabetes" AND "pathogenesis" AND "insulin resistance"
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from multiple authoritative textbooks. Let me compose the full answer.
Causes of Type 1 and Type 2 Diabetes Mellitus
TYPE 1 DIABETES (T1D)
Type 1 diabetes accounts for approximately 5-10% of all diabetes cases and is primarily an autoimmune disease caused by the selective destruction of pancreatic beta (β) cells. The result is an absolute deficiency of insulin.
1. Autoimmune Destruction of Beta Cells
The core mechanism is a T-cell-mediated immune attack on the insulin-secreting β cells of the pancreatic islets:
- CD8+ cytotoxic T cells directly kill β cells
- CD4+ Th1 cells secrete cytokines (IFN-γ, TNF) that injure β cells
- Macrophages also infiltrate the islets, forming a lesion called insulitis (chronic mononuclear cell infiltrate)
- Over time, islets become completely devoid of β cells, while α, δ, and other islet cells remain intact - demonstrating the specificity of the autoimmune attack
This autoimmune process begins months or years before clinical symptoms appear, and an 80-90% reduction in β-cell mass is required before symptomatic disease develops.
- Tietz Textbook of Laboratory Medicine, 7th Ed.; Goldman-Cecil Medicine
2. Autoantibodies (Markers of Autoimmunity)
Over 90% of newly diagnosed individuals have one or more autoantibodies:
| Autoantibody | Target | Prevalence in T1D |
|---|---|---|
| ICA | Islet cell cytoplasm | 75-85% at diagnosis |
| IAA | Insulin | ~80-90% in children <5 yrs |
| Anti-GAD65 | Glutamic acid decarboxylase | Present at diagnosis |
| Anti-IA-2 | Tyrosine phosphatase | Present at diagnosis |
| Anti-ZnT8 | Zinc transporter | Present at diagnosis |
Presence of two or more antibodies in normoglycemic relatives is highly predictive of developing T1D within 5 years.
- Henry's Clinical Diagnosis and Management; Goldman-Cecil Medicine
3. Genetic Factors
About 60 T1D susceptibility genes have been identified. The most important are:
- HLA class II genes (chromosome 6p): contribute ~50% of genetic risk
- DR4-DQ8 and DR3-DQ2 haplotypes are present in ~90% of children with T1D
- The DR3/DR4 double-haplotype carries the highest risk (~5%) and is seen in early-onset disease
- In contrast, DR15-DQ6 is highly protective, found in only 1% of T1D children vs. 20% of the general population
- Insulin gene (chromosome 11) - variable number of tandem repeats (VNTRs) regulate insulin expression in the thymus, influencing immune tolerance
- PTPN22, CTLA4 - regulate T-cell activation and self-tolerance
- IFIH1 (chromosome 2) - encodes a protein in innate immunity involved in recognizing viral RNA genomes; high levels may provoke exaggerated antiviral responses predisposing to autoimmunity
Familial risk: Affected fathers pass T1D to 6-9% of offspring; affected mothers to only 1-3%. Identical twin concordance is 30-40%, implying environmental factors also play a significant role.
- Goldman-Cecil Medicine; Robbins Pathologic Basis of Disease
4. Environmental Triggers
Because concordance in identical twins is only 30-40% (not 100%), environmental triggers are clearly important:
- Viral infections: Mumps, rubella, Coxsackie B virus, and cytomegalovirus have been associated with T1D. These viruses may contain molecules that mimic β-cell proteins (molecular mimicry), triggering autoimmunity in genetically predisposed individuals. SARS-CoV-2 has also been linked to new-onset T1D.
- Gut microbiome changes in early life
- Diet and hygiene hypothesis: Early exposure to cow's milk proteins, reduced gut microbial diversity
- The worldwide annual incidence has increased by 3-4% per year over the past 50-60 years, strongly pointing to environmental influences
5. Idiopathic Type 1 Diabetes
A small minority (<10%) have insulin-dependent diabetes with no evidence of autoimmunity - this is called idiopathic T1D (or "type 3c diabetes"). Causes include:
- Pancreatitis, pancreatic cancer, cystic fibrosis, hemochromatosis
- Drug-induced β-cell damage (interferon-γ, pentamidine, checkpoint inhibitor immunotherapy)
- Goldman-Cecil Medicine
TYPE 2 DIABETES (T2D)
Type 2 diabetes accounts for ~90-95% of all diabetes and involves two cardinal defects: peripheral insulin resistance and relative β-cell failure. There is no autoimmune basis.
1. Insulin Resistance
Insulin resistance - the failure of target tissues to respond normally to insulin - is the primary, early abnormality. It affects three key tissues:
- Skeletal muscle: Reduced GLUT-4 translocation to the cell surface → failure to take up and store glucose after meals → elevated postprandial glucose
- Liver: Failure to suppress gluconeogenesis → elevated fasting glucose
- Adipose tissue: Failure to suppress hormone-sensitive lipase → excess free fatty acid (FFA) release
At the molecular level: reduced tyrosine phosphorylation of the insulin receptor and IRS proteins impairs the insulin signaling cascade.
- Robbins Pathologic Basis of Disease; Guyton and Hall Medical Physiology
2. Obesity (the Most Important Acquired Risk Factor)
Over 80% of T2D patients are obese. Obesity - especially central/visceral adiposity - drives insulin resistance through multiple pathways:
- Excess free fatty acids (FFAs): Central adipose tissue is highly lipolytic. Excess FFAs overwhelm intracellular oxidation pathways, leading to accumulation of diacylglycerol (DAG), ceramides, and sphingolipids that block insulin receptor signaling
- Adipokines: Adipose tissue secretes pro-inflammatory cytokines (TNF-α, IL-6) and reduces adiponectin (which normally promotes insulin sensitivity); these shifts worsen insulin resistance
- Ectopic fat: Lipid deposition in liver and skeletal muscle ("lipotoxicity") further impairs insulin signaling
- Even modest weight loss can dramatically reduce insulin resistance
The incidence of T2D worldwide has risen in direct proportion to obesity rates. Importantly, individuals from Asia and the Middle East can develop T2D with a normal BMI if they have significant visceral adiposity ("metabolically obese, normal weight").
- Robbins Pathologic Basis of Disease
3. Beta-Cell Dysfunction
Initially, β cells compensate for insulin resistance by secreting more insulin (hyperinsulinemia). Over time, the β cells fail due to:
- Glucotoxicity: Chronic hyperglycemia damages β cells
- Lipotoxicity: Excess FFAs and toxic lipid metabolites promote β-cell apoptosis
- Islet amyloid: In T2D, islet β cells deposit islet amyloid polypeptide (IAPP/amylin), which is toxic to β cells and contributes to progressive β-cell loss (a key difference from T1D, which has insulitis)
- Decreased incretin effect: GLP-1 and GIP-mediated insulin secretion is blunted in T2D
- Late in the disease, β-cell mass is reduced and insulin administration becomes necessary
4. Genetic Factors
T2D has even stronger genetic penetrance than T1D - >90% concordance in identical twins. First-degree relatives have a 5-10-fold higher risk. Key susceptibility genes (identified by GWAS) include:
- TCF7L2 - most strongly associated gene; affects β-cell function
- PPARG - affects adipogenesis and fat distribution
- FTO - obesity-related gene
- KCNJ11 (Kir6.2) - potassium channel in β cells affecting insulin secretion
- Notably, no HLA linkage (unlike T1D)
Many of these genes affect β-cell function, fat distribution, or obesity.
5. Sedentary Lifestyle
Physical inactivity is an independent risk factor for T2D, separate from obesity. Exercise increases GLUT-4 translocation to the plasma membrane of skeletal muscle cells, directly improving insulin sensitivity. A sedentary lifestyle prevents this benefit.
6. Sleep Disorders and Circadian Disruption
Obstructive sleep apnea and circadian disruption (e.g., in shift workers) impair both insulin secretion and insulin action. GWAS studies have found associations between circadian-controlled genes and T2D risk.
7. Aging
T2D classically presents after age 30, most commonly at 50-60 years. Aging is associated with progressive decline in β-cell function and increased insulin resistance, even without obesity.
8. Other Risk Factors
- Gestational diabetes history
- Polycystic ovary syndrome (PCOS) - via insulin resistance
- Ethnic background (higher prevalence in South Asians, Hispanic/Latino, Black populations)
- Hypertension and dyslipidemia (metabolic syndrome)
Summary Comparison
| Feature | Type 1 | Type 2 |
|---|---|---|
| Mechanism | Autoimmune β-cell destruction | Insulin resistance + β-cell failure |
| Insulin levels | Absent (absolute deficiency) | Initially elevated, then reduced |
| Autoantibodies | Yes (GAD65, IA-2, ZnT8) | No |
| Body weight | Usually normal/thin | 80% overweight/obese |
| Genetics | HLA class II (DR3, DR4) | TCF7L2, PPARG, FTO (no HLA link) |
| Twin concordance | 30-40% | >90% |
| Islet pathology | Insulitis, β-cell depletion | Amyloid deposits, mild β-cell loss |
| Age of onset | Usually childhood/adolescence | Usually adult (but rising in children) |
| Environmental factors | Viral triggers, gut microbiome | Obesity, sedentary lifestyle, diet |
Sources: Robbins & Cotran Pathologic Basis of Disease (10th Ed.); Goldman-Cecil Medicine; Guyton & Hall Textbook of Medical Physiology; Tietz Textbook of Laboratory Medicine (7th Ed.); Henry's Clinical Diagnosis and Management by Laboratory Methods
This is a shared conversation. Sign in to Orris to start your own chat.